Human Vaccines

Human Vaccines


Global Human Vaccines Market to Reach US$71.4 Billion by 2030

The global market for Human Vaccines estimated at US$43.5 Billion in the year 2023, is expected to reach US$71.4 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2023-2030. Intramuscular & Subcutaneous Administration Route, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$58.7 Billion by the end of the analysis period. Growth in the Oral Administration Route segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.7 Billion While China is Forecast to Grow at 11.8% CAGR

The Human Vaccines market in the U.S. is estimated at US$11.7 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$16.8 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Human Vaccines Market - Key Trends and Drivers Summarized

Unveiling the Power of Human Vaccines: A Cornerstone of Modern Medicine

Human vaccines stand as one of the greatest achievements in public health, offering protection against a myriad of infectious diseases by training the immune system to recognize and combat pathogens. Comprising antigens that mimic disease-causing organisms, vaccines are crucial in preparing the immune system to fight diseases quickly and effectively. This mechanism has successfully led to the eradication and reduction of numerous life-threatening diseases, such as smallpox and polio, significantly lowering morbidity and mortality worldwide. Vaccines not only safeguard individuals but also contribute to herd immunity, preventing the spread of infections across communities and thereby securing population health globally.

Navigating New Frontiers: Innovations Enhancing Vaccine Efficacy and Safety

The landscape of vaccine technology is constantly evolving, incorporating novel methods that promise greater protection and safety. Traditional vaccine strategies, while effective, are now being enhanced with cutting-edge approaches like mRNA vaccines and recombinant technologies. These innovations offer precise targeting and rapid scalability, particularly highlighted by their role in addressing global challenges such as the COVID-19 pandemic swiftly. Furthermore, the development of adjuvants and improved delivery systems continues to revolutionize vaccine efficacy, broadening the horizons for combating more complex diseases and tailoring immunizations to diverse populations.

Emerging Trends Reshaping the Global Vaccine Sector

Global demographic and technological trends are reshaping the vaccine industry. The increase in international travel and urbanization elevates the risk of infectious disease transmission, amplifying the need for effective vaccination programs. Simultaneously, rising health consciousness and improved healthcare infrastructure are driving up vaccine uptake globally, especially in regions previously underserved. Technological advancements such as digital immunization tracking and AI in healthcare are also enhancing the reach and efficiency of vaccination campaigns, ensuring wider and more effective coverage.

What Drives the Growth in the Human Vaccines Market?

The growth in the human vaccines market is driven by several factors, including the increasing prevalence of infectious diseases, rising global health awareness, and advancements in vaccine research and development. Enhanced funding and investments by governments and global health organizations to eliminate infectious diseases contribute significantly to the expansion and innovation within the vaccine sector. The COVID-19 pandemic has particularly highlighted the critical role of vaccines in global health security, leading to unprecedented public and private partnerships focused on vaccine development and distribution. Moreover, demographic factors such as aging populations and the rise in chronic health conditions that increase susceptibility to infections necessitate continued vaccine development and uptake. Together, these dynamics underscore the vital role of vaccines in contemporary medicine and public health, ensuring ongoing investment and research in this essential field.

Select Competitors (Total 16 Featured) -
  • ALK - Abelló A/S
  • Altimmune, Inc.
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • Bharat Biotech
  • BiondVax Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Janssen Pharmaceuticals Inc.
  • MedImmune
  • Mitsubishi Tanabe Pharma
  • Pfizer Inc.
  • Sanofi Pasteur SA
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • SK BioScience
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Human Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advances in Genetic and Recombinant Technology Expands Vaccine Efficacy
Demand Grows for Pediatric and Adult Vaccines Globally
Rising Awareness and Education About Vaccine Preventable Diseases
Integration of AI and Machine Learning in Vaccine Development
Innovations in Vaccine Delivery Systems and Adjuvants
Vaccination Programs on Public Health Systems Spur Vaccines Usage & Penetration Among Susceptible Populations
Emergence of New Pathogens Drives Demand for Novel Vaccines
Vaccine to Prevent HIV Still in the Pipeline
R&D Interest in Personalized Cancer Vaccines Gains Momentum
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Human Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Intramuscular & Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Inactivated & Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
JAPAN
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
CHINA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
EUROPE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
FRANCE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
GERMANY
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
UNITED KINGDOM
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
AUSTRALIA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
INDIA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
LATIN AMERICA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
MIDDLE EAST
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
AFRICA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings